FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005477719> ?p ?o ?g. }

• W2005477719 endingPage "594" @default.
• W2005477719 startingPage "581" @default.
• W2005477719 abstract "제 1상 임상시험 계획에서 신약제의 최대허용용량을 추정하기 위해 전통적 방법인 표준 3+3계획과 모형중심의 베이지안 방법을 적용시킨 연속재평가방법이 주로 사용되고 있다. 본 논문에서는 치료불응 또는 재발된 백혈병이나 골수형성 이상증후군 환자를 대상으로 시행한 제 1상 임상시험의 연구계획을 개관하였다. 단순한 표준 3+3계획으로 환자확보 기간이 길어져 연구를 완성하지 못하고 때 이르게 중단할 수밖에 없는 실정에 반하여, 최근에 제시된 표준 3+1+1계획과 Rolling-6 계획은 연구기간을 크게 단축시킬 수 있다. 제1상 임상시험의 용량수준 선택과정에서 너무 보수적인 연구자의 태도는 최대허용용량의 정확한 추정을 불가능하게 한다. 새로운 환자에게 투여할 용량수준을 결정할 시점에서 용량제한 독성반응이 아직 나타나지 않은 환자의 관측시간 및 늦게 나타나는 환자의 독성반응 시간을 모두 감안한 연속재평가방법인 TITE-CRM계획이 유용하며, 이러한 CRM계획으로 진행되는 임상시험 시행 중 모의실험으로 각 용량수준에서 용량제한 독성반응율이 과대 또는 과소 추정되는지를 파악할 수 있음이 장점이다. 백혈병환자 대상의 임상연구에서 채택되는 제 1상 임상시험의 여러 연구계획의 장, 단점을 제시한다. The traditional method of 3+3 standard design and model-based Bayesian continual reassessment method (CRM) are commonly used in Phase I clinical trials to identify the maximal tolerated dose(MTD) of a new drug. In this paper we review clinical examples of Phase I trials that were carried out in patients with refractory or relapsed leukemia and myelodysplastic syndrome. The recently proposed 3+1+1 design and rolling-6 design can shorten the trial duration, when a very slow accrual of patients with a simple 3+3 standard design may result in the untimely termination of trials. Too conservative approaches in determining the dose levels in Phase I clinical trials can leave clinical investigators unable to accurately determine the MTD. When determining future patient doses, the designs that use a time-to-event CRM can cooperate late toxicities by accounting for the proportion of the observation period of each enrolled patient. With the CRM design, simulations under different scenarios during the trial are important in detecting the under- or over-estimation of the initial estimate of the dose-limiting toxicity rate for each dose level. We present the advantages and drawbacks of the designs used in Phase I clinical trials for leukemia patients." @default.
• W2005477719 created "2016-06-24" @default.
• W2005477719 creator A5062093949 @default.
• W2005477719 creator A5088444887 @default.
• W2005477719 date "2011-09-30" @default.
• W2005477719 modified "2023-09-25" @default.
• W2005477719 title "Continual Reassessment Method in Phase I Clinical Trials for Leukemia Patients" @default.
• W2005477719 cites W1569367256 @default.
• W2005477719 cites W1975124426 @default.
• W2005477719 cites W1975748182 @default.
• W2005477719 cites W1991060629 @default.
• W2005477719 cites W2000739200 @default.
• W2005477719 cites W2002649801 @default.
• W2005477719 cites W2003888937 @default.
• W2005477719 cites W2004133377 @default.
• W2005477719 cites W2005920914 @default.
• W2005477719 cites W2012307210 @default.
• W2005477719 cites W2045985885 @default.
• W2005477719 cites W2054383376 @default.
• W2005477719 cites W2055637937 @default.
• W2005477719 cites W2073567145 @default.
• W2005477719 cites W2076108528 @default.
• W2005477719 cites W2078274740 @default.
• W2005477719 cites W2102113607 @default.
• W2005477719 cites W2103973225 @default.
• W2005477719 cites W2104438003 @default.
• W2005477719 cites W2125300671 @default.
• W2005477719 cites W2138553618 @default.
• W2005477719 cites W2141086589 @default.
• W2005477719 cites W2141734928 @default.
• W2005477719 cites W2148233118 @default.
• W2005477719 cites W2149073952 @default.
• W2005477719 cites W2150405633 @default.
• W2005477719 cites W2158740848 @default.
• W2005477719 cites W2167228337 @default.
• W2005477719 cites W2169319915 @default.
• W2005477719 cites W2903792352 @default.
• W2005477719 cites W771394529 @default.
• W2005477719 doi "https://doi.org/10.5351/ckss.2011.18.5.581" @default.
• W2005477719 hasPublicationYear "2011" @default.
• W2005477719 type Work @default.
• W2005477719 sameAs 2005477719 @default.
• W2005477719 citedByCount "0" @default.
• W2005477719 crossrefType "journal-article" @default.
• W2005477719 hasAuthorship W2005477719A5062093949 @default.
• W2005477719 hasAuthorship W2005477719A5088444887 @default.
• W2005477719 hasBestOaLocation W20054777191 @default.
• W2005477719 hasConcept C121332964 @default.
• W2005477719 hasConcept C121955636 @default.
• W2005477719 hasConcept C126322002 @default.
• W2005477719 hasConcept C142424586 @default.
• W2005477719 hasConcept C143998085 @default.
• W2005477719 hasConcept C144133560 @default.
• W2005477719 hasConcept C148482608 @default.
• W2005477719 hasConcept C177713679 @default.
• W2005477719 hasConcept C2777334693 @default.
• W2005477719 hasConcept C2778461978 @default.
• W2005477719 hasConcept C2781426361 @default.
• W2005477719 hasConcept C31760486 @default.
• W2005477719 hasConcept C4577558 @default.
• W2005477719 hasConcept C535046627 @default.
• W2005477719 hasConcept C71924100 @default.
• W2005477719 hasConcept C87355193 @default.
• W2005477719 hasConceptScore W2005477719C121332964 @default.
• W2005477719 hasConceptScore W2005477719C121955636 @default.
• W2005477719 hasConceptScore W2005477719C126322002 @default.
• W2005477719 hasConceptScore W2005477719C142424586 @default.
• W2005477719 hasConceptScore W2005477719C143998085 @default.
• W2005477719 hasConceptScore W2005477719C144133560 @default.
• W2005477719 hasConceptScore W2005477719C148482608 @default.
• W2005477719 hasConceptScore W2005477719C177713679 @default.
• W2005477719 hasConceptScore W2005477719C2777334693 @default.
• W2005477719 hasConceptScore W2005477719C2778461978 @default.
• W2005477719 hasConceptScore W2005477719C2781426361 @default.
• W2005477719 hasConceptScore W2005477719C31760486 @default.
• W2005477719 hasConceptScore W2005477719C4577558 @default.
• W2005477719 hasConceptScore W2005477719C535046627 @default.
• W2005477719 hasConceptScore W2005477719C71924100 @default.
• W2005477719 hasConceptScore W2005477719C87355193 @default.
• W2005477719 hasIssue "5" @default.
• W2005477719 hasLocation W20054777191 @default.
• W2005477719 hasOpenAccess W2005477719 @default.
• W2005477719 hasPrimaryLocation W20054777191 @default.
• W2005477719 hasRelatedWork W2005477719 @default.
• W2005477719 hasRelatedWork W2052595716 @default.
• W2005477719 hasRelatedWork W2071907783 @default.
• W2005477719 hasRelatedWork W2170995876 @default.
• W2005477719 hasRelatedWork W2557725129 @default.
• W2005477719 hasRelatedWork W2898392983 @default.
• W2005477719 hasRelatedWork W3100833846 @default.
• W2005477719 hasRelatedWork W4286252388 @default.
• W2005477719 hasRelatedWork W4366432480 @default.
• W2005477719 hasRelatedWork W807851377 @default.
• W2005477719 hasVolume "18" @default.
• W2005477719 isParatext "false" @default.
• W2005477719 isRetracted "false" @default.
• W2005477719 magId "2005477719" @default.
• W2005477719 workType "article" @default.